These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2069792)

  • 21. The Helsinki Heart Study: basic design and randomization procedure.
    Mänttäri M; Elo O; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
    Eur Heart J; 1987 Oct; 8 Suppl I():1-29. PubMed ID: 3322826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
    Boden WE
    Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
    Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR
    Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD
    Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
    Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
    Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
    Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
    Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels.
    McKenney JM; Barnett MD; Wright JT; Proctor JP
    Arch Intern Med; 1992 Sep; 152(9):1781-7. PubMed ID: 1520045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group.
    Rubins HB; Robins SJ; Collins D
    Am J Cardiol; 1996 Sep; 78(5):572-5. PubMed ID: 8806347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population.
    Frick MH; Heinonen OP; Huttunen JK; Koskinen P; Mänttäri M; Manninen V
    Ann Med; 1993 Feb; 25(1):41-5. PubMed ID: 8435186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events.
    Phillips NR; Waters D; Havel RJ
    Circulation; 1993 Dec; 88(6):2762-70. PubMed ID: 8252689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
    Manninen V; Elo MO; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
    JAMA; 1988 Aug; 260(5):641-51. PubMed ID: 3164788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.
    Knipscheer HC; Nurmohamed MT; Van den Ende A; Plaat B; Pruijs HJ; Mulder WJ; Kastelein JJ
    J Intern Med; 1994 Oct; 236(4):377-84. PubMed ID: 7931040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
    Hay JW; Sterling KL
    Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
    Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ
    Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of fibric acid derivatives in the secondary prevention of coronary heart disease.
    Krakoff J; Vela BS; Brinton EA
    Curr Cardiol Rep; 2000 Sep; 2(5):452-8. PubMed ID: 10980914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients.
    Dachet C; Cavallero E; Martin C; Girardot G; Jacotot B
    Atherosclerosis; 1995 Feb; 113(1):1-9. PubMed ID: 7755644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
    Koskinen P; Mänttäri M; Manninen V; Huttunen JK; Heinonen OP; Frick MH
    Diabetes Care; 1992 Jul; 15(7):820-5. PubMed ID: 1516498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia.
    D'Agostino RB; Kannel WB; Stepanians MN; D'Agostino LC
    Am J Cardiol; 1992 Jan; 69(1):28-34. PubMed ID: 1729864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins.
    Bhatnagar D; Durrington PN; Mackness MI; Arrol S; Winocour PH; Prais H
    Atherosclerosis; 1992 Jan; 92(1):49-57. PubMed ID: 1575821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.